RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

MarketFest, The rational approach, as always, is to include a modest Cortex position as part of a well diversified bio portfolio, within a well diversified overall stock portfolio. We hear this advice over and over from seasoned investment experts, but never follow it (I'm as guilty as anyone, and have the losses to show for it over the years). What stock implosions should teach us is to DIVERSIFY, especially in this the riskiest of all sectors.

Looking at Cortex specifically, if I was still investing in individual stocks (which I'm not), I would be tempted to have a modest position in Cortex, along with the other 20 or so bio stocks I follow. There might be some tax loss selling in December, plus there's a financing coming, so the stock may remain weak for a while. I figure by May or so we'll get the FDA decision on dose liberalization, which will be a key event. Whether or not Stoll will actually disclose what the new liberalized dosing levels are is anyone's guess. You would think he was guarding the secrets of the Manhattan Project or something..